Biotechs struggle to get in.
Innovative biotechs, including Chinese companies, face unfamiliar regulation, language barriers and opaque channels.
Pharmaceutical Market Access
Your gateway to the Moroccan pharmaceutical market.
We help innovative pharmaceutical and biotech companies register and launch their medicines in Morocco — an entry point to French-speaking Africa — working with licensed local partners.
The challenge
Innovation often arrives late — or not at all.
Patients wait.
Treatments available elsewhere can take years to arrive — when they arrive at all.
Supply chains are being reorganised.
Europe is diversifying its pharmaceutical manufacturing base, which reshapes how access and production are organised.
What we do
Six levers, one asset-light model.
Sourcing
We identify and qualify molecules with a genuine access pathway in Morocco and Africa.
Regulatory engineering
We prepare and coordinate marketing-authorisation dossiers in international format.
Partnership structuring
We build the agreement between the product owner and the licensed local operator who will carry it.
Market access
Pricing, reimbursement, distribution partners: we coordinate the route to market.
Clinical development
We help organise trials and evidence generation with Moroccan hospital and university sites.
Near-shore manufacturing
We help structure manufacturing partnerships in Morocco, to European standards, serving Europe and Africa.
A two-way hub
Innovation in, production out.
ChinaIncoming innovation
MoroccoRegistration · clinical evidence · manufacturing
Africa & EuropeMarket access · export
Our model, stated plainly
We orchestrate. Licensed partners operate.
What we do
- Identify and qualify molecules
- Prepare and coordinate registration dossiers
- Structure partnerships and negotiate agreements
- Drive market access
What we do not do for medicines
- Hold the marketing authorisation
- Import or distribute medicines
- Manufacture medicines ourselves
For medicines, these activities are the responsibility of licensed pharmaceutical establishments. We work alongside them; we do not replace them. This scope applies to our pharmaceutical activity only — our industrial biotechnology activity follows a different model.
Why Morocco
A strategic position for pharmaceutical access.
USD 1.5 bnMoroccan pharmaceutical market in 2024, after average annual growth of nearly 8% since 2020Source [1]
64%of medicines in circulation in Morocco are importedSource [1]
An established industrial base
A dense pharmaceutical industry, recognised expertise and a dedicated medicines agency.
Regulation that is evolving
Growing alignment on international standards, assessed product by product.
A door into Africa
Linguistic, diplomatic and economic ties with French-speaking Africa.
On Europe's doorstep
The EU–Morocco Association Agreement provides duty-free access to the EU market for goods that meet the rules of origin [2].
These elements are assessed case by case: we never quote a regulatory timeline before verifying it for your product.
Sources
- LesEco.ma, « Industrie pharmaceutique : le Maroc s’affirme sur la scène africaine », 10 February 2025 — leseco.ma
- European External Action Service (EEAS), « Commerce et investissement », EU–Morocco relations (PDF) — eeas.europa.eu
Our trajectory
Step by step, in stages.
- STEP 1
First advisory and market-access mandates
- STEP 2
First licensing agreements and regulatory filings
- STEP 3
Expansion into French-speaking Africa
- STEP 4
Selective distribution and near-shore production, with licensed partners
Discuss a pharmaceutical project.
Biotech, laboratory, distributor or clinical site: let's find the right access pathway together.